  Abbreviations, acronyms & symbols                                                           
  ----------------------------------- ---------------------------------------- --- ---------- ------------------------------------------------
  ACE                                 = Angiotensin-converting enzyme              LVEF       = Left ventricular ejection fraction
  AT                                  = Anaerobic threshold                        NYHA       = New York Heart Association
  BMI                                 = Body mass index                            PETCO~2~   = End-tidal partial pressure of carbon dioxide
  BTPS                                = Body temperature pressure standard         PETO~2~    = End-tidal partial pressure of oxygen
  CET                                 = Cardiopulmonary exercise test              RER        = Respiratory exchange ratio
  CHF                                 = Chronic heart failure                      RR         = Respiratory rate
  CMDC                                = Carbon monoxide diffusion capacity         SpO~2~     = Blood oxygen saturation
  EOV                                 = Exercise oscillatory ventilation           SVC        = Slow vital capacity
  FEV~1~                              = Forced expiratory volume in 1 second       VCO~2~     = Carbon dioxide production
  FV                                  = Flow-volume                                VE         = Ventilation production
  FVC                                 = Forced vital capacity                      VO~2~      = Oxygen consumption
  HR                                  = Heart rate                                             

INTRODUCTION
============

Cardiovascular ischemic events are the leading cause of chronic heart failure (CHF), which is a syndrome that is generally characterized by the classic left ventricular systolic impairment with consequent muscular peripheral dysfunction^\[[@r1]\]^ caused by not only the low cardiac output, but also by medications, oxidative stress, and chronic hypoxemia, among others^\[[@r2]\]^. An important outcome of this peripheral muscular dysfunction is the reduced functional capacity, negatively affecting the patients\' autonomy and consequently their quality of life^\[[@r2]\]^.

Many parameters are known as independent markers of severity and predictors of morbidity and mortality in this group of patients. The maximal inspiratory pressure has been shown as an independent variable to quantify the survival rate of these patients^\[[@r3]\]^ because it may reflect the inspiratory muscle weakness, usually witnessed in them. Furthermore, the handgrip strength has also been reported as an isolated parameter of CHF severity^\[[@r4]\]^. In this context, we may highlight the significance of the cardiopulmonary exercise test (CET). It is a useful tool that induce physiological responses in exercise conditions that might not appear at rest conditions.

From the parameters obtained in the CET, many of them have been described as negatively influenced by CHF progression. It is quite well known that patients with CHF present low functional status and exercise capacity, with reduced peak oxygen consumption (VO~2~)^\[[@r5],[@r6]\]^. Another powerful CET variable that may reflect the severity of these patients and, more specifically, the pulmonary congestion is the ventilation production (VE)/ carbon dioxide production (VCO~2~) slope, which shows the ventilatory inefficiency, mainly in those who have values \> 34, strongly characterizing pulmonary congestion^\[[@r7],[@r8]\]^. Also, the presence of oscillatory ventilation in rest or during exercise is being considered as an important variable with prognostic value of CET^\[[@r9],[@r10]\]^. Besides this importance, there is still no standardization for obtaining and interpreting exercise oscillatory ventilation (EOV)^\[[@r11]\]^.

Therefore, the aim of the present study is to characterize the presence of EOV and to relate it with other clinical variables in patients with CHF.

METHODS
=======

Study Design
------------

This is an observational and transversal study with convenience sample.

Patients
--------

Forty-six men with CHF were recruited by clinical assessment. Inclusion criteria were previous history of stable symptomatic CHF due to left ventricular systolic dysfunction, documented for at least six months (left ventricular ejection fraction \[LVEF\]: \< 45%), New York Heart Association (NYHA) class between II-III, and clinical stability for at least three months. Patients were excluded from study if they had clinical and/or functional evidence of obstructive pulmonary disease (forced expiratory volume in 1 second \[FEV~1~\]/forced vital capacity \[FVC\] \< 70% in pulmonary test)^\[[@r12]\]^, exercise-induced asthma, unstable angina or significant cardiac arrhythmias, and myocardial infarction within the previous six months; also, none of the subjects were tobacco users, alcohol dependents, or users of addicting drugs. No patient had been submitted to cardiovascular rehabilitation. All subjects presented the same clinical management, optimized medications, and were clinically stable. The eligible participants signed a written informed consent and the study protocol was approved by the Ethics Committee of Institution (protocol 238/06 and protocol 970.098).

Experimental Procedure
----------------------

The research was performed in an air-conditioned laboratory, with temperature between 22ºC and 24ºC, and relative humidity between 50 and 60%, always in the same period of the day (between 8 am and 12 pm). In the day before the test, patients were warned to avoid the intake of stimulating drinks, not to perform physical activity, and to have light meals and at least 8 hours of sleep. First, the volunteers were familiarized with the experimental set and involved researchers. Before the test begun, the patients were examined to verify if the recommendations were followed. Then, the systolic and diastolic arterial blood pressure and the peripheral oxygen saturation were measured, and it was performed auscultation.

Pulmonary Function
------------------

Pulmonary function tests, measuring slow vital capacity (SVC), FVC, FEV~1~, and FEV~1~/FVC ratio, were carried out using the CardiO~2~ System (Medical Graphics Corporation, St. Paul, MO, USA). For comparative purposes, reference values from Knudson et al.^\[[@r13]\]^, expressed in body temperature pressure standard (BTPS) conditions, were used. Carbon monoxide diffusion capacity (CMDC) was assessed by simple respiration model and static volumes were assessed by whole-body plethysmography. Technical procedures and the acceptability and reproducibility criteria were defined according to norms recommended by the American Thoracic Society^\[[@r14]\]^.

Ventilatory and Metabolic Variables During CET
----------------------------------------------

Ventilatory and metabolic variables were obtained by a computer connected to an ergospirometric measurement system (CardiO~2~ System), using the Breeze Suite 6 software package. Tidal volume was obtained by a Pitot pneumotachometer connected to the CardiO~2~ System and attached to a facial mask - which was selected considering the volunteer\'s face size and providing an adequate fit in order to avoid air leakage. The device presents in real time applied power values (W) and pedaling speed (rpm), as well as VO~2~, VCO~2~, minute ventilation (VE), heart rate (HR), and blood oxygen saturation (SpO~2~). Ventilatory equivalent values (VE/VO~2~ and VE/VCO~2~), respiratory exchange ratio (RER), end-tidal partial pressure of oxygen (P~ET~O~2~) and carbon dioxide (P~ET~CO~2~), flow-volume (FV), and respiratory rate (RR) were also calculated and registered. The power applied to the cycle ergometer during exercise protocols was controlled by the system through an interface with the bicycle.

Data Analysis
-------------

The following parameters were analyzed in CET variables:

### First Ventilatory Threshold (At) Obtained

Visual analysis of VO~2~ and VCO~2~ correlation curves, VE/VO~2~, and P~ET~O~2~ were graphically represented in moving mean values each eight respiratory cycles. Subsequently, three independent observers determined the anaerobic threshold (AT) under the following situations: 1) V-slope: breaking point from linearity in VO~2~ and VCO~2~ correlation curves; 2) VE/VO~2~: nadir point of this ratio, ensuring that a systematic increase occurs from it; and 3) P~ET~O~2~: nadir point of this variable, from which a systematic increase begins. The CET data were set from the beginning of the ventilatory and metabolic variables responses to power output increments till the end of the exercise. Analysis of each observer was performed in an independent manner, on a 15 inches monitor (SyncMaster 550V, Samsung) connected to the MedGraphics software.

### Exercise Oscillatory Ventilation (EOV)

The presence of periodic breathing was obtained by the analysis of ventilation data, and it was confirmed if there were three consecutive cycles with minimal average amplitude of 5 l in these data (peak value minus the average of two in-between consecutive nadirs), as suggested by Leite et al.^\[[@r15]\]^.

### VE/VCO~2~ slope

VE and VCO~2~ data were analyzed from the beginning of the exercise till peak. Data were input into spreadsheet software (Microsoft Excel) to calculate VE/VCO~2~ slope via least squares linear regression (y = mx + b, m = slope).

VE/VCO~2~ \> 34 and peak VO~2~ \< 14 ml/kg/min were used to assess patients\' severity.

Statistical Analyses
--------------------

Statistical analyses were performed using the SigmaPlot version 11.0.0.007 (for Windows(r)) with level of significance set at 0.05. Data were submitted to a normality test (Shapiro-Wilk). As a normal distribution was observed, parametric statistical tests were used. For intergroup comparisons, the t-Student pared test was applied. Demographics, anthropometrics, and clinical data were presented as means with standard deviation.

RESULTS
=======

Forty-six male patients were recruited; 22 patients were excluded and 24 were included in the present study ([Figure 1](#f1){ref-type="fig"}).

Fig. 1Flowchart of the present study. CHF = chronic heart failure; CET = cardiopulmonary exercise test.

[Table 1](#t1){ref-type="table"} shows age and anthropometric and clinical characteristics of these patients, as well as their functional status and the CET variables with their prognostic thresholds. Body mass index (BMI) average showed that most of the patients were overweight and they were in NYHA functional class II and III. Among the 24 included patients, 16 presented EOV.

###### 

Anthropometrics, clinical and cardiopulmonary exercise test (CET) data of the patients included in the present study.

  Variables                             (n=24)
  ------------------------------------- --------------
  Age (years)                           53.1±13.6
  Height (cm)                           169±7
  Mass (kg)                             76.27±12.83
  BMI (kg/m^2^)                         26.5±3.8
  Functional status                      
      NYHA II/III                       9/15
  CET                                    
      Peak VO~2~ (ml/min)               1135.0±325.8
      Peak VO~2~ (ml/kg/min)            15.1±4.1
      AT VO~2~ (l/min)                  655.8±189.1
      AT VO~2~ (ml/kg/min)              8.7±2.5
      Peak P~ET~CO~2~                   29.7±7.8
      VE/VCO~2~                         40.1±15.7
      EOV Yes/No                        16/8
  Prognostic values                      
      VE/VCO~2~ \> 34 (n/%)             14/46
      PeakVO~2~ \< 14 ml/kg/min (n/%)   10/25
  Medications                            
      Diuretics (n)                     14
      Digitalics (n)                    9
      Beta-blockers (n)                 24
      ACE-inhibitors (n)                15

Mean ± standard deviation. ACE=angiotensin-converting enzyme; AT=anaerobic threshold; BMI=body mass index; EOV=exercise oscillatory ventilation; NYHA=New York Heart Association; P~ET~CO~2~=end-tidal partial pressure of carbon dioxide; VE/VCO~2~=ventilation/carbon dioxide production; VO~2~=oxygen consumption

[Figure 2](#f2){ref-type="fig"} shows the data obtained from patients with EOV (EOV+) and patients who did not present EOV (EOV-) on incremental CET with other parameters obtained from the CET, as well as their clinical variables and age. There was no difference between EOV+ and EOV- groups.

Fig. 2Analysis of age, cardiopulmonary exercise test and clinical variables of exercise oscillatory ventilation (EOV+) population and non-EOV (EOV-) population. (A) Peak oxygen consumption (ml/kg/min). (B) Peak oxygen consumption (ml/min). (C) Oxygen consumption (ml/kg/min) at anaerobic threshold (AT). (D) Oxygen consumption at AT (ml/min). (E) VE/VCO2 slope. (F) Age. (G) Left ventricular ejection fraction (LVEF) (%). (H) New York Heart Association (NYHA) functional class.

Also, there was no difference on age, clinical variables and parameters of the CET data obtained from patients with EOV *and* VE/VCO~2~ slope \> 34 when compared to patients with EOV *or* VE/VCO~2~ slope \> 34, as shown on [Table 2](#t2){ref-type="table"}. Such analysis was performed to verify if the patients who presented these two concomitant responses had a more severe status than those who didn\'t.

###### 

Analysis of cardiopulmonary exercise test (CET) parameters of patients with exercise oscillatory ventilation (EOV+) and VE/VCO~2~ \>34 or just one of these variables.

                           EOV (+) and VE/VCO~2~ \>34   EOV (+) or VE/VCO~2~ \> 34   *P* value
  ------------------------ ---------------------------- ---------------------------- -----------
  LVEF (%)                 31.5±4.5                     30±6.5                       0.51
  Peak VO~2~ (ml/kg/min)   13.8±3.7                     16.1±5.1                     0.25
  Peak VO~2~ (ml/min)      1075.7±373.5                 1199.0±349.9                 0.47
  AT VO~2~ (ml/kg/min)     8.3±2.3                      9.4±3.1                      0.39
  AT VO~2~ (ml/min)        648.1±205.7                  704.1±222.9                  0.57
  Age (years)              55.2±13.3                    52.1±14.8                    0.64
  NYHA                     2.7±0.5                      2.6±0.5                      0.68
  Peak P~ET~O~2~ (mmHg)    109.1±4.3                    104.9±7.4                    0.13
  Peak P~ET~CO~2~ (mmHg)   26.±3.7                      31.±10.3                     0.34
  Peak workload (W)        84.9±27.6                    91.3±31.0                    0.64
  HR (bpm)                 123.5±27.0                   122.5±19.8                   0.92

Mean ± standard deviation. *P* value \< 0.05

AT=anaerobic threshold; HR=heart rate; LVEF=left ventricle ejection fraction; NYHA=New York Heart Association; PetCO~2~=end-tidal partial pressure of carbon dioxide; P~ET~O~2~=end-tidal partial pressure of oxygen; VE/VCO~2~=ventilation/carbon dioxide production; VO~2~=oxygen consumption

DISCUSSION
==========

The present study\'s main findings are: (i) no difference between CET variables in patients with EOV and non-EOV; (ii) the absence of difference on functional variables between CHF patients with EOV *and* VE/VCO~2~ \> 34 and those with EOV *or* VE/VCO~2~ \> 34; iii) the presence of EOV and peak VO~2~ \< 14 ml/kg/min in 25% of the patients, as well as EOV and VE/VCO~2~ \> 34 in 46% of them.

Anthropometric data of CHF patients showed that they were overweight and that 15 of the 24 evaluated patients were classified as NYHA functional class III. Furthermore, they had a poor exercise performance on CET, which can be seen by the value of peak VO~2~ (15.1 ml/kg/min), presenting low peak workload values. The literature shows that CHF patients exhibit a low peak VO~2~ ^\[[@r16]\]^ as a marker of exercise intolerance caused by many factors of this disease as the low cardiac output, pulmonary congestion, and alterations of metabolism on peripheral and ventilatory muscle fibers that lead to a muscular dysfunction with impact on exercise tolerance. Peak VO~2~ is also a prognostic variable of CET^\[[@r5],[@r6]\]^.

Other CET variables showed similarities between our study and the literature, specifically when it comes to the coexisting presence of EOV and other bad prognostic variables, such as VE/VCO~2~ \> 34 and peak VO~2~ \< 14 ml/kg/min^\[[@r17]\]^. One study has showed that the presence of the combination EOV and VE/VCO~2~ \> 34 is particularly more alarming because of the risk for adverse cardiac events^\[[@r18]\]^. Otherwise, our results do not agree with the literature when it comes to the worst response of CET variables on EOV population, described as lower peak VO~2~, higher VE/VCO~2~ slope, and lower rest and peak P~ET~CO~2~, when compared to non-EOV population^\[[@r17]\]^. Hypotheses for these findings are the heterogeneity of exercise protocols in the literature and the absence of a gold standard to verify the presence of EOV in patients with profile and clinical status similar to our subjects. In a meta-analysis about the assessment of EOV, Cornelis et al.^\[[@r11]\]^ have suggested the use of Corrà et al.^\[[@r19]\]^ criteria, although none of the criteria available appears to be superior. This criterion should be applied to a constant load protocol since the VE data may not vary more than 15% compared to the mean of rest VE data, which is a physiological response expected on the incremental exercise protocol. Also, the presence of EOV may be longer than 60% of the exercise time. For the results presented, we used Leite et al.^\[[@r15]\]^ criteria because these are not so subjective since the presence of EOV is not calculated through time, but as a continuous variation of the VE data with an waxing and waning pattern, and it is not influenced by the time of its appearance, but by its amplitude. Finally, we believe that Leite et al.^\[[@r15]\]^ criteria could be more appropriate to assess EOV during incremental exercise test.

Even though the trigger mechanisms of EOV are not totally understood, the main hypotheses are circulatory delay, increased chemosensivity, increased ergoreflex signaling, and/or pulmonary congestion^\[[@r17]\]^. The reduced cardiac output leads to a delayed lung-chemoreceptor circulation (peripheral/central); this and the inefficient control of VE caused by increased chemosensitivity lead to an exaggerated response of the ventilation^\[[@r20]\]^. From the hemodynamic view, there is an uncoupling on the right ventricle to lung circulation, and a pulmonary edema due to a high ventricle filling pressure even when these patients are clinically stable and on optimized drug therapy^\[[@r20]\]^.

Studies that evaluated the prognostic power of EOV obtained by the analysis of ventilatory pattern of CHF patients when submitted to a CET suggest that this variable seems to be the most important in the CET, even with better prognostic values than VE/VCO~2~ slope^\[[@r21]\]^. Additionally, the presence of EOV combined with higher values of VE/VCO~2~, mainly \> 34, is even more alarming and powerful to predict adverse cardiac events on CHF population^\[[@r18]\]^, characterizing that these two ventilatory variables reflect the worst control on ventilation and ventilatory inefficiency and may be translated into a better prognostic definition^\[[@r20]\]^. In the present study, the comparison between patients with EOV and VE/VCO~2~ \> 34 and patients with only one of these showed no statistical difference on CET ventilatory variables, age, nor their clinical status, such as LVEF. It is already known that the presence of EOV is not altered by LVEF, since Guazzi et al.^\[[@r22]\]^ showed no difference in incidence of EOV in CHF patients with normal or reduced LVEF. It suggests the power of EOV as an independent CET marker of worst prognostic because it represents the poor hemodynamic and ventilatory adjust to physical exercise and did not correlate with other ventilatory and metabolic CET variables with prognostic values.

Some studies focused on treatment of EOV and showed that the pathological pattern of ventilation in EOV population can be modulated and even disappear. Three studies evaluating pharmacological therapy with inodilator (malrinone)^\[[@r23]\]^ and selective pulmonary vasodilator (sildenafil)^\[[@r24]\]^ have shown some attenuation on EOV. In another study based on aerobic training, for three months, 71% of the patients with stable congestive heart failure showed a good EOV response^\[[@r25]\]^. These studies evaluated stable patients on optimized drug therapy, which suggests that maybe EOV does not respond to standard treatment for CHF, requiring other approaches than pharmacological interventions, such as physical exercise.

Based on the present study\'s findings, it is important to encourage further studies about EOV in CHF and other patients for a better comprehension of the role of EOV, as well as to establish a gold standard pattern to verify the presence of this variable in different diseases and levels of severity. Finally, this knowledge improves therapeutic strategies.

Limitations
-----------

The absence of gold standard in obtaining EOV must be considered, also some tool to evaluate peripheral muscular strength would give information that could help the interpretation of the findings. Results may not be extrapolated to more severe patients. Finally, this study was made with a convenience sample and more subjects should be recruited to consolidate our findings.

CONCLUSION
==========

The present study showed that there was an incidence of patients with EOV and lower peak VO~2~ and higher VE/VCO~2~ slope values, but there was no difference on other prognostic variables. In addition, no influence of the EOV presence on other parameters of CET in this population was observed, suggesting that this CET variable may be an independent marker of severity in CHF patients.
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